Anthera Pharma' (NASDAQ: ANTH) Blisibimod received FDA orphan drug status for treatment of patients with immunoglobulin A ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE